✦ LIBER ✦

Combined chemotherapy with cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for patients with advanced Hodgkin's disease. An alternative program to MOPP

✍ Scribed by Clara D. Bloomfield; Raymond B. Weiss; Ignacio Fortuny; Gerald Vosika; B. J. Kennedy

Publisher: John Wiley and Sons
Year: 1976
Tongue: English
Weight: 565 KB
Volume: 38
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(197607)38:1<42::aid-cncr2820380108>3.0.co;2-u

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Chemotherapy With cyclophosphamide, vinb

Chemotherapy With cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for hodgkin disease: Fourteen-year follow-up results

✍ Kathryn E. Dusenbery; Bruce A. Peterson; Dr. Clara D. Bloomfield 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 570 KB

Thirty-eight patients with advanced Hodgkin disease were treated with a combination of cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) from 1970 to 1973 and followed prospectively. Long-term results after a median follow-up of 14 years are reported. Seventeen of the 28 complete re

Cyclophosphamide, vinblastine, procarbaz

Cyclophosphamide, vinblastine, procarbazine and prednisone with CCNU and vinblastine maintenance for advanced Hodgkin's disease

✍ Charles H. Diggs; Peter H. Wiernik; John A. Levi; Larry K. Kvols 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 485 KB 👁 2 views

Hybrid chemotherapy consisting of cyclop

Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced hodgkin disease

✍ Silvia Montoto; Mireia Camós; Armando López-Guillermo; Francesc Bosch; Francisco 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 1 views

## BACKGROUND. Combination chemotherapy, including hybrid regimens, is the standard treatment for patients with advanced Hodgkin disease (HD). Although a prolonged complete response (CR) is achieved in up to 70 -80% of patients, long term complications, such as secondary leukemia, are of concern. C